Biotinylated Human BTLA (31-134) Protein, Fc, Avitag™

Biotinylated Human BTLA (31-134), Fc, Avitag (BTA-H82F8) is expressed from human 293 cells (HEK293) . It contains AA Lys 31 - Thr 134 (Accession # Q7Z6A9) .

Product Specifications

Background

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Specifications

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 40.5 kDa. The protein migrates as 48-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

Q7Z6A9

Expression Region

Lys 31 - Thr 134

Host

HEK293

Target

BTLA

Conjugation

Biotin-labeled

Tag

C-Fc & C-Avi

Source

Human

Stability

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

95%

Bioactivity

Immobilized Human HVEM, Fc Tag (Cat. No. HVM-H5258) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BTLA (31-134), Fc,Avitag (Cat. No. BTA-H82F8) with a linear range of 0.039-1.25 μg/mL (QC tested).